Methods using TCF II

Details Methods using TCF II Methods using TCF II

2006-10-03

2006-10-03

Borin, Michael (Department: 1631)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C530S350000

Reexamination Certificate

active

07115568

ABSTRACT:
The present invention provides an agent for preventing and/or treating cachexia comprising TCF-II as an effective ingredient. An agent for preventing and treating cachexia caused by cancer, acquired immunodeficient syndrome (AIDS), cardiac diseases, infectious disease, shock, burn, endotoxinemia, organ inflammation, surgery, diabetes, collagen diseases, radiotherapy, chemotherapy is provided by the present invention.

REFERENCES:
patent: 3904753 (1975-09-01), Sonenberg et al.
patent: 4076701 (1978-02-01), Burton et al.
patent: 4481137 (1984-11-01), Ohnishi et al.
patent: 4490549 (1984-12-01), Johnson
patent: 4650674 (1987-03-01), Aggarwal et al.
patent: 4777241 (1988-10-01), Irikura et al.
patent: 4822605 (1989-04-01), Powell
patent: 4870163 (1989-09-01), Rubin et al.
patent: 5091511 (1992-02-01), Sone et al.
patent: 5328836 (1994-07-01), Shima et al.
patent: 5362716 (1994-11-01), Kmiecik et al.
patent: 5432267 (1995-07-01), Kusama et al.
patent: 5510327 (1996-04-01), Hayasaka et al.
patent: 5547856 (1996-08-01), Godowski et al.
patent: 5587359 (1996-12-01), Higashio et al.
patent: 5589451 (1996-12-01), Wilson
patent: 5606029 (1997-02-01), Degen
patent: 5648233 (1997-07-01), Yamaguchi et al.
patent: 5648273 (1997-07-01), Bottaro et al.
patent: 5658742 (1997-08-01), Higashio et al.
patent: 5703047 (1997-12-01), Wilson
patent: 5703048 (1997-12-01), Roos et al.
patent: 5707624 (1998-01-01), Nickoloff et al.
patent: 5714461 (1998-02-01), Masunaga et al.
patent: 5760177 (1998-06-01), Iwanaga et al.
patent: 5776464 (1998-07-01), Nakamura
patent: 5821223 (1998-10-01), Rubin et al.
patent: 5998370 (1999-12-01), Arai
patent: 6306827 (2001-10-01), Kinosaki et al.
patent: 6333309 (2001-12-01), Higashio et al.
patent: 2218864 (1997-10-01), None
patent: 2100720 (2003-03-01), None
patent: 2116192 (2005-05-01), None
patent: 0 322 084 (1989-06-01), None
patent: 0 456 188 (1991-11-01), None
patent: 0 498 680 (1992-08-01), None
patent: 0 519 728 (1992-12-01), None
patent: 0 587 311 (1994-03-01), None
patent: 0 588 477 (1994-03-01), None
patent: 0 604 184 (1994-06-01), None
patent: 0 604 185 (1994-06-01), None
patent: 0 462 277 (1995-06-01), None
patent: 0 672 685 (1995-09-01), None
patent: 0 724 884 (1996-07-01), None
patent: 0 462 549 (1996-08-01), None
patent: 0 757 994 (1997-02-01), None
patent: 0 821 969 (1998-02-01), None
patent: 0 461 560 (1998-11-01), None
patent: 0 891 778 (1999-01-01), None
patent: 0 539 590 (1999-03-01), None
patent: 0 914 829 (1999-05-01), None
patent: 0 925 791 (1999-06-01), None
patent: 0 950 416 (1999-10-01), None
patent: 0 982 037 (2000-01-01), None
patent: 0 612 530 (2000-08-01), None
patent: 0 653 211 (2001-10-01), None
patent: 10-68400 (1989-03-01), None
patent: 5-244976 (1993-09-01), None
patent: 6-40935 (1994-02-01), None
patent: 6-40938 (1994-02-01), None
patent: 06040934 (1994-02-01), None
patent: 6-56692 (1994-03-01), None
patent: 6-116299 (1994-04-01), None
patent: 06340546 (1994-12-01), None
patent: 081176007 (1996-07-01), None
patent: 08231418 (1996-09-01), None
patent: 10-29951 (1998-02-01), None
patent: 10-194986 (1998-07-01), None
patent: 10-273446 (1998-10-01), None
patent: WO90/10651 (1990-09-01), None
patent: WO91/03254 (1991-03-01), None
patent: WO93/08821 (1993-05-01), None
patent: WO93/13066 (1993-07-01), None
patent: WO94/14845 (1994-07-01), None
patent: WO96/20004 (1996-07-01), None
patent: WO96/20214 (1996-07-01), None
patent: WO96/28423 (1996-09-01), None
patent: WO96/32960 (1996-10-01), None
patent: WO98/40096 (1998-09-01), None
patent: WO98/41230 (1998-09-01), None
patent: WO98/43665 (1998-10-01), None
patent: WO99/47155 (1999-09-01), None
Anscher et al., “Role of Transforming Growth Factor-.beta. and Hepatocyte Growth Factor in Late Normal Tissue Effects of Radiation,”Radiat. Oncol. Invest. 1 (6), 305-13 (1994).
Argiles et al, “The Role of Cytokines in Cancer Cachexia,” Department di Bioquimica i Biologia Molecular, Facultat de Biologia, Universitat de Barcelona, Spain;Med Res Rev. vol. 19 (3):223-48 (May 1999).
Bervetello et al., “Heterogeneous Response of Adipose Tissue to Cancer Cachexia,”Braz. J. Med. Biol. Res., vol. 34(9), pp. 1161-1167 (2001).
Bossola et al., “Serum Tumour Necrosis Factor-α Levels in Cancer Patients are Discontinuous and Correlate with Weight Loss,”European Journal of Clinical Investigation, vol. 30, pp. 1107-1112 (2000).
Ceconi, et al., “Tumor Necrosis Factor in Congestive Heart Failure: A Mechanism of Disease for the New Millennium?”Progress in Cardiovascular Diseases, vol. 41, No. 1, Suppl. 1, pp. 25-30, (Jul./Aug. 1998).
Chang, et al., “The Role of Cytokines in the Catabloc Consequences of Infection and Injury, Journal of Parental and Enteral Nutrition,” vol. 22, No. 3, 156-166 (May/Jun. 1998).
Fujiwara et al., “Stimulation of Liver Growth by Exogenous Human Hepatocyte Growth Factor in Normal and Partially Hepatectomized Rats,”Hepatology, 18(6):1443-1449 (1993).
Gohda et al., “Purification and Partial Characterization of Hepatocyte Growth Factor from Plasma of a Patient with Fulminant Hepatic Failure,”The American Society for Clinical Investigation, vol. 81, pp. 414-419 (Feb. 1988).
Raymond C. Harris, “Growth Factors and Cytokines in Acute Renal Failure,”Supplement to Advances in Renal Replacement Therapy, vol. 4, No. 2, Suppl. 1, pp. 43-53 (Apr. 1997).
Haslett, “Anticytokine Approaches to the Treatment of Anorexia and Cachexia, Seminars in Oncology,” vol. 25, No. 2 Suppl. 6, pp. 53-57, (Apr. 1998).
Higashio et al., “Identity of a Tumor Cytotoxic Factor From Human Fibroblasts and Hepatocyte Growth Factor,”Biochemical and Biophysical Research Communications, 170(1):397-404, (Jul. 16, 1990).
Higashio et al., “Tumor cytotoxic activity of HGF-SF,”Experientia Supplementum, 65:351-368 (1993).
Humes et al., “Renal Tubule Cell Repair following Acute Renal Injury,”Mineral and Electrolyte Metabolism, vol. 21, pp. 353-365, (Jul./Oct. 1995).
Kinosaki et al., “Identification of heparin-binding stretches of a naturally occurring deleted variant of hepatocyte growth factor (dHGF),”Biochimica et Biophysica Acta, 1384(1): 93-102 (1998).
Kinosaki et al., “Analysis of deleted variant of hepatocyte growth factor by alanine scanning mutagenesis: identification of residues essential for its biological function and generation of mutants with enhanced mitogenic activity on rat hepatocytes,”FEBS Letters, 434(1-2):165-169 (1998).
Llovera, et al., “Protein Turnover in Skeletal Muscle of Tumor-Bearing Transgenic Mice Overexpressing the Soluble TNF Receptor-1,”Cancer Letters, 130, 19-27 (1998).
Llovera, et al., “Role of TNF Receptor 1 in Protein Turnover During Cancer Cachexia Using Gene Knockout Mice,”Molecular and Cellular Endocrinology, 142, 183-189 (1998).
Masunaga et al., “Amelioration of Disordered Hepatic Protein Synthesis by the Deleted Form of Hepatocyte Growth Factor in Models of Liver Failure in Rats,”Journal of Pharmacy and Pharmacology, 48:876-879 (1996).
Masunaga et al., “Deleted form of hepatocyte growth factor (dHGF) increases the number of platelets in rats with liver cirrhosis,”Liver, 17(4):192-197 (1997).
Masunaga et al., “Preventive effects of the deleted form of hepatocyte growth factor against various liver injuries,”European Journal of Pharmacology, vol. 342, pp. 267-279 (1998).
Matsuda et al., “Hepatocyte Growth Factor Suppresses the Onset of Liver Cirrhosis and Abrogates Lethal Hepatic Dysfunction in Rats,”J. Biochem, vol. 118, No. 3, pp. 643-649 (1995).
Matsumoto et al., “HGF: its organotrophic role and therapeutic potential,” Therapeutic Potential of HGF, Ciba Foundation Symposium 212:198-214; discussion 211-4 (1997).
Matsumoto et al., “Roles of HGF as a pleiotropic factor in organ regeneration,”Hepatocyte Growth Factor-Scatter Factor, (1993).
Miyazawa et al., “Molecular Cloning and

Affiliated with

Also associated with

Rating

Methods using TCF II does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods using TCF II, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods using TCF II will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3624777